{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:10:52Z","timestamp":1791414652005,"version":"4.3.3"},"reference-count":61,"publisher":"Informa UK Limited","issue":"11","funder":[{"DOI":"10.13039\/501100004622","name":"Dutch Cancer Society","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Roche Pharmaceuticals"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Pharmacogenomics"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.2217\/pgs.15.70","type":"journal-article","created":{"date-parts":[[2015,8,12]],"date-time":"2015-08-12T11:01:33Z","timestamp":1439377293000},"page":"1275-1284","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":106,"title":["Translating\n            <i>DPYD<\/i>\n            Genotype into DPD Phenotype: Using the\n            <i>DPYD<\/i>\n            Gene Activity Score"],"prefix":"10.1080","volume":"16","author":[{"given":"Linda M","family":"Henricks","sequence":"first","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands"},{"name":"Department of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carin ATC","family":"Lunenburg","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Meulendijks","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands"},{"name":"Department of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Gelderblom","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemieke","family":"Cats","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology &amp; Hepatology, The Netherlands Cancer Institute, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse J","family":"Swen","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy &amp; Toxicology, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan HM","family":"Schellens","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands"},{"name":"Department of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands"},{"name":"Division of Pharmacoepidemiology &amp; Clinical Pharmacology, Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk-Jan","family":"Guchelaar","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy &amp; Toxicology, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2015,8,12]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1074"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-2571(00)00011-X"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.11.72"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-06-0327"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13167-010-0041-2"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.2174\/157016007780077176"},{"issue":"48","key":"e_1_3_2_9_1","first-page":"A4934","article-title":"Prevention of severe toxicity from capecitabine, 5-fluorouracil and tegafur by screening for DPD-deficiency","volume":"156","author":"Deenen MJ","year":"2012","unstructured":"Deenen MJ , CatsA , MandigersCMet al. Prevention of severe toxicity from capecitabine, 5-fluorouracil and tegafur by screening for DPD-deficiency . Ned. Tijdschr. Geneeskd.156 ( 48 ), A4934 ( 2012 ).","journal-title":"Ned. Tijdschr. Geneeskd."},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.29.15_suppl.3606"},{"key":"e_1_3_2_11_1","first-page":"22","volume-title":"8eme Congres de Physiologie, de Pharmacologie et de Therapeutique.","author":"Boisdron-Celle M","year":"2013","unstructured":"Boisdron-Celle M , CapitainO , MetgesJP , LecomteT , Matysiak-BudnikT , MorelA . Severe fluoropyrimidines toxicities: screen effectively for DPD deficiencies . Presented at : 8eme Congres de Physiologie, de Pharmacologie et de Therapeutique.Angers, France , 22 \u2013 24April 2013 ."},{"key":"e_1_3_2_12_1","volume-title":"6th Santorini Conference Biologie Prospective 2012.","author":"Siffert W","year":"2012","unstructured":"Siffert W . Pharmacogenetics in daily routine clinical practice . Presented at : 6th Santorini Conference Biologie Prospective 2012.Santorini, Greece , 30 September\u20132 October 2012 ."},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-010814-124835"},{"key":"e_1_3_2_14_1","volume-title":"2013 ASCO Annual Meeting.","author":"B Boisdron-Celle M","year":"2013","unstructured":"B Boisdron-Celle M , CapitainO , MetgesJPet al. Prevention of 5-FU-induced health-threatening toxicity by pretherapeutic DPD deficiency screening: medical and economic assessment of a multiparametric approach . Presented at : 2013 ASCO Annual Meeting.Chicago, USA , 31 May\u201314 June 2013 ."},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-2482"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00439-010-0879-3"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.09.28"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1042\/bj3640157"},{"key":"e_1_3_2_19_1","unstructured":"US Food and Drug Administration . Pharmaocgenomic information capecitabine\/fluorouracil ( 2015 ). www.fda.gov ."},{"key":"e_1_3_2_20_1","unstructured":"European Medicines Agency . Summary of Product Characteristics capecitabine ( 2015 ). www.ema.europa.eu ."},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2013.172"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.34"},{"key":"e_1_3_2_23_1","unstructured":"Royal Dutch Society for the Advancement of Pharmacy . Background information Pharmacogenetics \u2013 Dihydropyriminde dehydrogenase (DPD) ( 2015 ). www.kennisbank.knmp.nl ."},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01799841"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199812000-00001"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju298"},{"issue":"5","key":"e_1_3_2_27_1","first-page":"1149","article-title":"Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency","volume":"7","author":"Van Kuilenburg AB","year":"2001","unstructured":"Van Kuilenburg AB , MullerEW , HaasjesJet al. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency . Clin. Cancer Res.7 ( 5 ), 1149 \u2013 1153 ( 2001 ).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(97)00261-X"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-3858"},{"issue":"12","key":"e_1_3_2_30_1","first-page":"4705","article-title":"Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene","volume":"6","author":"Van Kuilenburg AB","year":"2000","unstructured":"Van Kuilenburg AB , HaasjesJ , RichelDJet al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene . Clin. Cancer Res.6 ( 12 ), 4705 \u2013 4712 ( 2000 ).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1520"},{"issue":"3","key":"e_1_3_2_32_1","first-page":"768","article-title":"Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype","volume":"8","author":"Johnson MR","year":"2002","unstructured":"Johnson MR , WangK , DiasioRB . Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype . Clin. Cancer Res.8 ( 3 ), 768 \u2013 774 ( 2002 ).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03257473"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/15257770802145009"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.13.116"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-013-0936-8"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1177\/147323001003800313"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.4182"},{"issue":"2","key":"e_1_3_2_39_1","first-page":"325","article-title":"Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer","volume":"17","author":"Salgado J","year":"2007","unstructured":"Salgado J , ZabaleguiN , GilC , MonrealI , Rodr\u00edguezJ , Garc\u00eda-FoncillasJ . Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer . Oncol. Rep.17 ( 2 ), 325 \u2013 328 ( 2007 ).","journal-title":"Oncol. Rep."},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0320"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.GIM.0000118061.66602.A5"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200210000-00007"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2006.09.006"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2209"},{"issue":"9","key":"e_1_3_2_45_1","first-page":"2832","article-title":"Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5\u2032-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls","volume":"7","author":"Raida M","year":"2001","unstructured":"Raida M , SchwabeW , H\u00e4uslerPet al. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5\u2032-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls . Clin. Cancer Res.7 ( 9 ), 2832 \u2013 2839 ( 2001 ).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.262"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-015-2698-7"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-1784"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.1857"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200004000-00002"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29025"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.14.126"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1105"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270004268911"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26595"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1177\/147323001003800413"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.patbio.2008.05.001"},{"key":"e_1_3_2_58_1","first-page":"17","volume-title":"2010 Meeting on Pharmacogenomics and Personalized Medicine.","author":"Largiad\u00e8r CR","year":"2010","unstructured":"Largiad\u00e8r CR , AmstutzU , FroehlichTKet al. The dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity: a classic reborn? Presented at : 2010 Meeting on Pharmacogenomics and Personalized Medicine.Cold Spring Harbor, NY, USA , 17 \u2013 21November 2010 ."},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2003.030825"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100406"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.2217\/14622416.8.3.257"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1517\/14622416.3.4.485"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2013.25"}],"container-title":["Pharmacogenomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/pgs.15.70","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T14:44:36Z","timestamp":1715957076000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/pgs.15.70"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":61,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["10.2217\/pgs.15.70"],"URL":"https:\/\/doi.org\/10.2217\/pgs.15.70","relation":{},"ISSN":["1462-2416","1744-8042"],"issn-type":[{"value":"1462-2416","type":"print"},{"value":"1744-8042","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ipgs20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ipgs20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2015-08-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}